INDUSTRY LEADER
Geneuity and it's parent company MPLN, are industry leaders in advanced molecular level testing. MPLN's impressive history includes:
2007 - Developed abl gene mutation asay to detect Gleevec resistance in CML
2006 - 07 Developed JAK2 V617F qualitatitve and quantitative assays for diagnosis and monitoring of chronic myeloproliferative disorders
2006 - Introduced Luminex technology platform with plans to offer molecular screening of pathogens for hospital infection control programs
2005 - Began clinical trial testing for new human papillomavirus (HPV) test development
2004 - 05 Developed and introduced quantitative PCR for minimal residual disease (MRD) testing in chronic myelogenous leukemia and acute promyelocytic leukemia (CML, APL)
2004 - Received Molecular Center of Excellence designation by Roche Molecular Systems, Inc.
2003 - Introduced T cell receptor and Immunoglobulin heavy chain gene re-arrangements by PCR
2002 - Introduced Vysis® UroVysion™ Bladder Cancer screen
2002 - Validated Hybrid Capture II HPV assay on SurePath™ Test Pack
2001 - Implemented MPLNet, MPLN’s proprietary laboratory information system customized for molecular diagnostics
2001 - Introduced real time PCR for infectious disease testing
2001 - 510K clearance for Nucleic Acid Transport Media. Developed by MPLN founder Roger Hubbard, PhD and marketed by Medical Packaging, Inc.